Nutralife Biosciences Stock Current Ratio
Nutralife Biosciences fundamentals help investors to digest information that contributes to Nutralife Biosciences' financial success or failures. It also enables traders to predict the movement of Nutralife Pink Sheet. The fundamental analysis module provides a way to measure Nutralife Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nutralife Biosciences pink sheet.
Nutralife |
Nutralife Biosciences Company Current Ratio Analysis
Nutralife Biosciences' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Nutralife Biosciences Current Ratio | 0.10 X |
Most of Nutralife Biosciences' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nutralife Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
CompetitionIn accordance with the recently published financial statements, Nutralife Biosciences has a Current Ratio of 0.1 times. This is 96.56% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The current ratio for all United States stocks is 95.37% higher than that of the company.
Nutralife Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nutralife Biosciences' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Nutralife Biosciences could also be used in its relative valuation, which is a method of valuing Nutralife Biosciences by comparing valuation metrics of similar companies.Nutralife Biosciences is currently under evaluation in current ratio category among its peers.
Nutralife Fundamentals
| Return On Equity | -14.26 | |||
| Return On Asset | -0.28 | |||
| Operating Margin | (3.80) % | |||
| Current Valuation | 11.61 M | |||
| Shares Outstanding | 176.62 M | |||
| Shares Owned By Insiders | 45.95 % | |||
| Price To Book | 85.51 X | |||
| Price To Sales | 14.09 X | |||
| Revenue | 626.62 K | |||
| Gross Profit | 83.59 K | |||
| EBITDA | (5.71 M) | |||
| Net Income | (5.83 M) | |||
| Cash And Equivalents | 51.8 K | |||
| Total Debt | 10 K | |||
| Current Ratio | 0.10 X | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (487.39 K) | |||
| Earnings Per Share | (0.03) X | |||
| Number Of Employees | 12 | |||
| Beta | -0.9 | |||
| Market Capitalization | 6.62 M | |||
| Total Asset | 4.85 M | |||
| Net Asset | 4.85 M |
Thematic Opportunities
Explore Investment Opportunities
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Consideration for investing in Nutralife Pink Sheet
If you are still planning to invest in Nutralife Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Nutralife Biosciences' history and understand the potential risks before investing.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |